BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 26626094)

  • 1. A preliminary investigation of the role of the transcription co-activators YAP/TAZ of the Hippo signalling pathway in canine and feline mammary tumours.
    Beffagna G; Sacchetto R; Cavicchioli L; Sammarco A; Mainenti M; Ferro S; Trez D; Zulpo M; Michieletto S; Cecchinato A; Goldschmidt M; Zappulli V
    Vet J; 2016 Jan; 207():105-111. PubMed ID: 26626094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of the Hippo signalling effectors YAP and TAZ in canine mammary gland hyperplasia and malignant transformation of mammary tumours.
    Rico C; Boerboom D; Paquet M
    Vet Comp Oncol; 2018 Dec; 16(4):630-635. PubMed ID: 30117264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hippo signaling pathway in companion animal diseases, an under investigated signaling cascade.
    Budel SJ; Penning MM; Penning LC
    Vet Q; 2021 Dec; 41(1):172-180. PubMed ID: 33945400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wnt/β-Catenin and Hippo Pathway Deregulation in Mammary Tumors of Humans, Dogs, and Cats.
    Sammarco A; Gomiero C; Sacchetto R; Beffagna G; Michieletto S; Orvieto E; Cavicchioli L; Gelain ME; Ferro S; Patruno M; Zappulli V
    Vet Pathol; 2020 Nov; 57(6):774-790. PubMed ID: 32807036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of TAZ and YAP crosstalk with TGFβ signalling in canine osteosarcoma suggests involvement of hippo signalling in disease progression.
    Luu AK; Schott CR; Jones R; Poon AC; Golding B; Hamed R; Deheshi B; Mutsaers A; Wood GA; Viloria-Petit AM
    BMC Vet Res; 2018 Nov; 14(1):365. PubMed ID: 30477496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statins downregulate YAP and TAZ and exert anti-cancer effects in canine mammary tumour cells.
    Vigneau AL; Rico C; Boerboom D; Paquet M
    Vet Comp Oncol; 2022 Jun; 20(2):437-448. PubMed ID: 34881506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COX-2, mPGES-1 and EP2 receptor immunohistochemical expression in canine and feline malignant mammary tumours.
    Millanta F; Asproni P; Canale A; Citi S; Poli A
    Vet Comp Oncol; 2016 Sep; 14(3):270-80. PubMed ID: 24824420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metallothionein expression in canine and feline mammary and melanotic tumours.
    Dincer Z; Jasani B; Haywood S; Mullins JE; Fuentealba IC
    J Comp Pathol; 2001; 125(2-3):130-6. PubMed ID: 11578128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular phenotype of primary mammary tumours and distant metastases in female dogs and cats.
    Beha G; Muscatello LV; Brunetti B; Asproni P; Millanta F; Poli A; Benazzi C; Sarli G
    J Comp Pathol; 2014; 150(2-3):194-7. PubMed ID: 24060151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic trial of fluvastatin in a cell line xenograft model of canine mammary gland cancer.
    Atmane MI; Vigneau AL; Beaudry F; Rico C; Boerboom D; Paquet M
    Vet Comp Oncol; 2023 Dec; 21(4):634-645. PubMed ID: 37709554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of steroid receptor expression in normal, dysplastic, and neoplastic canine and feline mammary tissues.
    Millanta F; Calandrella M; Bari G; Niccolini M; Vannozzi I; Poli A
    Res Vet Sci; 2005 Dec; 79(3):225-32. PubMed ID: 16054892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the Hippo Signaling Pathway for Tissue Regeneration and Cancer Therapy.
    Juan WC; Hong W
    Genes (Basel); 2016 Aug; 7(9):. PubMed ID: 27589805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced PTEN protein expression and its prognostic implications in canine and feline mammary tumors.
    Ressel L; Millanta F; Caleri E; Innocenti VM; Poli A
    Vet Pathol; 2009 Sep; 46(5):860-8. PubMed ID: 19429983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXCR4 expression in feline mammary carcinoma cells: evidence of a proliferative role for the SDF-1/CXCR4 axis.
    Ferrari A; Petterino C; Ratto A; Campanella C; Wurth R; Thellung S; Vito G; Barbieri F; Florio T
    BMC Vet Res; 2012 Mar; 8():27. PubMed ID: 22417013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant P-cadherin expression is associated to aggressive feline mammary carcinomas.
    Figueira AC; Gomes C; de Oliveira JT; Vilhena H; Carvalheira J; de Matos AJ; Pereira PD; Gärtner F
    BMC Vet Res; 2014 Nov; 10():270. PubMed ID: 25424750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of TopBP1 in canine mammary neoplasia in relation to histological type, Ki67, ERalpha and p53.
    Morris JS; Nixon C; King OJ; Morgan IM; Philbey AW
    Vet J; 2009 Mar; 179(3):422-9. PubMed ID: 18314357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of vascular endothelial growth factor and its receptor Flk-1/KDR in promoting tumour angiogenesis in feline and canine mammary carcinomas: a preliminary study of autocrine and paracrine loops.
    Millanta F; Silvestri G; Vaselli C; Citi S; Pisani G; Lorenzi D; Poli A
    Res Vet Sci; 2006 Dec; 81(3):350-7. PubMed ID: 16556453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormonal background of canine and feline mammary tumours.
    Rutteman GR; Misdorp W
    J Reprod Fertil Suppl; 1993; 47():483-7. PubMed ID: 8229967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of the glutamine metabolism-related proteins glutaminase 1 and glutamate dehydrogenase in canine mammary tumours.
    Ryu JE; Park HK; Choi HJ; Lee HB; Lee HJ; Lee H; Yu ES; Son WC
    Vet Comp Oncol; 2018 Jun; 16(2):239-245. PubMed ID: 29266697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical evaluation of STAT3-p-tyr705 expression in feline mammary gland tumours and correlation with histologic grade.
    Petterino C; Ratto A; Podestà G; Drigo M; Pellegrino C
    Res Vet Sci; 2007 Apr; 82(2):218-24. PubMed ID: 16934302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.